Paclitaxel encapsulated in cationic liposomes increases tumor microvessel leakiness and improves therapeutic efficacy in combination with cisplatin

Clinical Cancer Research

Volumn 14, Issue 14, 2008, Pages 4603-4611

  Strieth, Sebastian ^a   Eichhorn, Martin E ^a   Werner, Alexander ^b   Sauer, Birgitta ^c   Teifel, Michael ^d   Michaelis, Uwe ^c   Berghaus, Alexander ^a   Dellian, Marc ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b BSL Bioservice Scientific Laboratories GmbH   (Germany)

^c MediGene AG   (Germany)

^d Zentaris GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ENDOTAG 1; LIPOSOME; PACLITAXEL; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CATION;

AMELANOTIC MELANOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; CANCER INHIBITION; CELL INTERACTION; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; ENCAPSULATION; ENDOTHELIUM CELL; HISTOPATHOLOGY; LEUKOCYTE; MALE; NONHUMAN; PRIORITY JOURNAL; SYRIAN HAMSTER; TUMOR GROWTH; TUMOR VASCULARIZATION; ANIMAL; CAPILLARY; CAPILLARY PERMEABILITY; DRUG EFFECT; EXPERIMENTAL MELANOMA; HAMSTER; NEOVASCULARIZATION (PATHOLOGY); VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAPILLARIES; CAPILLARY PERMEABILITY; CATIONS; CISPLATIN; CRICETINAE; LIPOSOMES; MALE; MELANOMA, EXPERIMENTAL; MESOCRICETUS; NEOVASCULARIZATION, PATHOLOGIC; PACLITAXEL;

EID: 51649088789     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4738     Document Type: Article

References (29)

1. Hobbs SK, Monsky WL, Yuan F, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A 1998;95:4607-12.
2. Morikawa S, Baluk P, Kaidoh T, et al. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 2002;160: 985-1000.
3. McDonald DM, Baluk P. Significance of blood vessel leakiness in cancer. Cancer Res 2002;62: 5381-5.
4. Chang YS, di Tomaso E, McDonald DM, et al. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci U S A 2000;97:14608-13.
5. Denekamp J. The tumour microcirculation as a target in cancer therapy: a clearer perspective. Eur J Clin Invest 1999;29:733-6.
6. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004;10:415-27.
7. Thurston G, McLean JW, Rizen M, et al. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J Clin Invest 1998; 101:1401-13.
8. Schmitt-Sody M, Strieth S, Krasnici S, et al. Neovascular targeting therapy: paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy. Clin Cancer Res 2003;9:2335-41.
9. Strieth S, Eichhorn ME, Sauer B, et al. Neovascular targeting chemotherapy: encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature. Int J Cancer 2004;110:117-24.
10. Strieth S, Nussbaum CF, Eichhorn ME, et al. Tumor-selective vessel occlusions by platelets after vascular targeting chemotherapy using paclitaxel encapsulated in cationic liposomes. Int J Cancer 2008; 122:452-60.
11. Eichhorn ME, Strieth S, Krasnici S, et al. Protamine enhances uptake of cationic liposomes in angiogenic microvessels. Angiogenesis 2004;7:133-41.
12. Michel CC, Curry FE. Microvascular permeability. Physiol Rev 1999;79:703-61.
13. Tozer GM, Prise VE, Wilson J, et al. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability Cancer Res 2001;61:6413-22.
14. Krasnici S, Werner A, Eichhorn ME, et al. Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels. Int J Cancer 2003;105: 561-7.
15. Asaishi K, Endrich B, Goetz A, Messmer K. Quantitative analysis of microvascular structure and function in the amelanotic melanoma A-Mel-3. Cancer Res 1981;41:1898-904.
16. Endrich B, Hammersen F, Goetz A, Messmer K. Microcirculatory blood flow, capillary morphology and local oxygen pressure of the hamster amelanotic melanoma A-Mel-3. J Natl Cancer Inst 1982;68: 475-85.
17. Yuan F, Leunig M, Berk DA, Jain RK. Microvascular permeability of albumin, vascular surface area. and vascular volume measured in human adenocarcinoma LS174Tusing dorsal chamber in SCID mice. Microvasc Res 1993;45:269-89.
18. Klyscz T. Jünger M, Jung F, Zeintl H. Capimage-a new kind of computer-assisted video image analysis system for dynamic capillary microscopy. Biomed Tech (Berl) 1997;42:168-75.
19. Zeintl H, Sack FU, Intaglietta M, Messmer K. Computer assisted leukocyte adhesion measurement in intravital microscopy. Int J Microcirc Clin Exp 1989;8: 293-302.
20. Weiss N, Delius M, Gambihler S, et al. Influence of the shock wave application mode on the growth of A-Mel 3 and SSK2 tumors in vivo. Ultrasound Med Biol 1990;16:595-605.
21. Beauregard DA, Hill SA, Chaplin DJ, Brindle KM. The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability. Cancer Res 2001;61:6811-5.
22. Langley RR, Russell J, Eppihimer MJ, et al. Quantification of murine endothelial cell adhesion molecules in solid tumors. Am J Physiol 1999;277: H1156-66.
23. Jain RK. Normalizing tumor vasculature with antiangiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7:987-9.
24. Yuan F, Dellian M, Fukumura D, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995;55:3752-6.
25. Dellian M, Yuan F, Trubetskoy VS, Torchilin VP, Jain RK. Vascular permeability in a human tumour xenograft: molecular charge dependence. Br J Cancer 2000;82:1513-8.
26. Luedemann S, Eichhorn ME, Strieth S, et al. Antivascular tumor therapy by paclitaxel encapsulated in cationic lipid complexes (EndoTAG-1): comparison of metronomic and maximum tolerated dose treatment. Angiogenesis 2006;9: 29.
27. Rubin K, Sjoquist M, Gustafsson AM, et al. Lowering of tumoral interstitial fluid pressure by prostaglandin E(1) is paralleled by an increased uptake of ([51])Cr-EDTA. Int J Cancer 2000;86:636-43.
28. Goto H, Yano S, Matsumori Y, et al. Sensitization of tumor-associated endothelial cell apoptosis by the novel vascular-targeting agent ZD6126 in combination with cisplatin. Clin Cancer Res 2004;10:7671-6.
29. Kerbel RS. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 2006; 312:1171-5.